C. Day

J. George, E. Bugianesi, E. Vanni, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease

G. Alexander, M. Allison, H. Yki-Jărvinen, 2014, Cell cycle.

Non‐alcoholic steatohepatitis: Definitions and pathogenesis

C. Day, C. Day, S. Saksena, 2002, Journal of gastroenterology and hepatology.

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

C. Day, 2002, Gut.

S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility.

Q. Anstee, C. Day, 2012, Journal of hepatology.

Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease

J. Newton, David E. J. Jones, C. Day, 2009, Clinical Autonomic Research.

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

L. Valenti, S. Fargion, Q. Anstee, 2012, Journal of hepatology.

Genetic and Environmental Susceptibility to Non-Alcoholic Fatty Liver Disease

C. Day, 2010, Digestive Diseases.

Non-alcoholic steatohepatitis — therapeutic interventions

C. Day, 2009 .

Non-alcoholic steatohepatitis: metabolic syndrome of the liver

C. Day, 2008 .

Non-alcoholic fatty liver disease: the mist gradually clears.

C. Day, Nimantha Mark Wilfred de Alwis, 2008, Journal of hepatology.

Genes and nonalcoholic fatty liver disease

C. Day, Nimantha Mark Wilfred de Alwis, 2008, Current diabetes reports.

Human liver stem cells originate from the canals of hering

P. Chinnery, G. Hudson, A. Burt, 2009, Hepatology.

No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease.

H. Friess, A. Kolb, D. Schuppan, 2008, Alcoholism, clinical and experimental research.

From fat to inflammation.

C. Day, 2006, Gastroenterology.

OPINION Nonalcoholic fatty liver disease: new treatments

Q. Anstee, C. Day, T. Hardy, 2015 .

Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver

M. Bennett, A. Burt, C. Day, 1995, The Lancet.

Title : Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study

Mia, M. Nelson, Yufeng Shen, 2016 .

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

M. Pirmohamed, G. Aithal, A. Hasnat, 2014, European Journal of Clinical Pharmacology.

Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis

J. Grove, C. Day, A. Daly, 1997, Hepatology.

Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management

Q. Anstee, C. Day, A. Daly, 2013 .

PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease

Y. Kuo, H. Nischalke, A. Singal, 2015, The American Journal of Gastroenterology.

Patatin‐like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease

P. Haber, C. Day, D. Seth, 2010, Hepatology.

Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease

G. Targher, C. Day, 2011, Hepatology.

Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

V. de Lédinghen, F. Nevens, P. Bedossa, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

How to Diagnose Nonalcoholic Fatty Liver Disease

Q. Anstee, C. Day, Nimantha Mark Wilfred de Alwis, 2016, Digestive Diseases.

Clinical Spectrum and Therapy of Non-Alcoholic Steatohepatitis

C. Day, 2012, Digestive Diseases.

Sugar sweetened beverages and fatty liver disease: Rising concern and call to action.

M. Abdelmalek, C. Day, 2015, Journal of hepatology.

Non-alcoholic steatohepatitis: another disease of affluence

C. Day, O. James, 1999, The Lancet.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

I. Guha, G. Aithal, P. Trembling, 2013, Hepatology.

Non-alcoholic fatty liver disease: a massive problem.

C. Day, 2011, Clinical medicine.

ResearchElevated endotoxin levels in non-alcoholic fatty liver disease

H. Sharada, C. Day, D. Alastair, 2015 .

Researchendotoxin levels in non-alcoholic fatty liver disease

A. Burt, H. Sharada, C. Day, 2010 .

Elevated endotoxin levels in non-alcoholic fatty liver disease

A. Burt, H. Sharada, C. Day, 2010, Journal of Inflammation.

Management strategies in alcoholic liver disease

H. Tilg, C. Day, 2007, Nature Clinical Practice Gastroenterology &Hepatology.

Risk of all-cause and cardiovascular mortality in patients with chronic liver disease

G. Zoppini, G. Targher, C. Day, 2010, Gut.

Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control

G. MacGowan, Roy Taylor, M. Trenell, 2015, Cardiovascular Diabetology.

Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease

David E. J. Jones, M. Vidali, E. Albano, 2004, Hepatology.

Detection and characterization of novel polymorphisms in the CYP2E1 gene.

I. de Waziers, J. Grove, C. Day, 1998, Pharmacogenetics.

Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease

J. Grove, A. Burt, C. Day, 1998, Gut.

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

H. Cordell, M. Allison, M. Vacca, 2021, Journal of hepatology.

Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity.

C. Day, A. Daly, S. Ballestri, 2011, Gastroenterology.

GUTJNL216077-225110 1265..1269

A. Burt, C. Day, S. McPherson, 2022 .

A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

H. Reeves, M. Hudson, C. Day, 2009, BMC Cancer.

CD14 promoter polymorphism associated with risk of NASH

C. Day, 2002 .

Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome

G. Zoppini, M. Muggeo, G. Targher, 2009, Journal of endocrinological investigation.

No evidence for involvement of type 1 collagen structural genes in 'genetic predisposition' to alcoholic cirrhosis.

B. Sykes, C. Day, D. Ogilvie, 1992, Journal of hepatology.

Genetic predisposition to alcoholic liver disease.

C. Day, M. Bassendine, C. Day, 1992, Gut.

Inhibition of rat hepatocyte proliferation by transforming growth factor β and glucagon is associated with inhibition of ERK2 and p70 S6 kinase

C. Day, L. Agius, S. Yeaman, 1999, Hepatology.

Current and future therapeutic strategies in NAFLD.

C. Day, N. Mark, W. P. Gamini De Alwis, 2010, Current pharmaceutical design.

A coffee with your brandy, Sir?

C. Day, Stuart Kendrick, 2007, Journal of hepatology.

379 Characteristics and Long-Term Prognosis of Lean Patients With Nonalcoholic Fatty Liver Disease

E. Bjornsson, J. George, E. Bugianesi, 2014 .

Liver disorder and the HFE locus.

C. Day, S. Stewart, 2001, QJM : monthly journal of the Association of Physicians.

AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease

P. Trerotoli, G. Giannelli, H. Reeves, 2008, BMC Cancer.

Chapter 28 – Alcoholic Liver Disease

C. Day, S. Stewart, 2012 .

Alcohol—Risks and Mechanisms of Damage

C. Day, 1994, Journal of the Royal College of Physicians of London.

The natural history of nonalcoholic fatty liver: A follow‐up study

M. Bennett, A. Burt, C. Day, 1995, Hepatology.

Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.

H. Reeves, Q. Anstee, C. Day, 2015, Journal of hepatology.

Genetics of alcoholic and nonalcoholic fatty liver disease.

Q. Anstee, C. Day, A. Daly, 2011, Seminars in liver disease.

The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: Consistent evidence from case-control and intra-familial allelic association studies

A. Alisi, M. Manco, C. Day, 2007 .

Genetic evidence for a role for gut flora in the pathogenesis of NASH in humans

C. Mathew, C. Day, J. Leathart, 2006 .

Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value

G. Marchesini, J. Dufour, P. Bedossa, 2015 .

Apoptosis in alcoholic hepatitis: a novel therapeutic target?

C. Day, 2001, Journal of hepatology.

The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype.

J. Grove, C. Day, A. Daly, 1998, Pharmacogenetics.

A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis.

M. Hudson, D. Jones, C. Day, 2007, Journal of hepatology.

No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis.

J. Grove, D. Jones, C. Day, 1998, Journal of hepatology.

Prednisolone or pentoxifylline for alcoholic hepatitis.

M. Thursz, P. Richardson, J. O'grady, 2015, The New England journal of medicine.

Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation.

C. Day, S. Yeaman, N. Elabbadi, 2005, Biochimie.

Disorders of Coagulation and Hemostasis in Abdominal Obesity: Emerging Role of Fatty Liver

G. Zoppini, G. Targher, P. Moghetti, 2010, Seminars in thrombosis and hemostasis.

CYP2C9 polymorphism and warfarin dose requirements.

G. Aithal, C. Day, A. Daly, 2002, British journal of clinical pharmacology.

Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease

David C. Jones, M. Vidali, R. Rolla, 2003, Hepatology.

Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

G. Targher, L. Bertolini, C. Day, 2007, Diabetes Care.

Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

E. Bugianesi, E. Vanni, E. Galmozzi, 2010, Hepatology.

Genetics of Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease

C. Day, Nimantha Mark Wilfred de Alwis, Nimantha Wilfred de Alwis1 , 2, 2007, Seminars in liver disease.

Obstructive sleep apnoea is common in adults with biopsy-proven non-alcoholic fatty liver disease.

J. Newton, C. Day, S. West, 2015, Sleep medicine.

Transforming Growth Factor β Increases the Activity of Phosphatidate Phosphohydrolase-1 in Rat Hepatocytes

C. Day, L. Agius, S. Yeaman, 1997 .

Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease

C. Day, J. Leathart, A. Daly, 2003 .

The inheritance of alcoholic liver disease.

C. Day, M. Bassendine, 1998, Bailliere's clinical gastroenterology.

A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'?

Q. Anstee, C. Day, 2012, Journal of Hepatology.

Digoxin-like factors in liver disease.

C. Day, O. James, 1989, Journal of hepatology.

Treatment of alcoholic liver disease

C. Day, 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Who Gets Alcoholic Liver Disease: Nature or Nurture?

C. Day, 2000, Journal of the Royal College of Physicians of London.

Genetics of Alcoholic Liver Disease

Q. Anstee, C. Day, A. Daly, 2015, Seminars in Liver Disease.

The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial.

L. Vale, M. Thursz, P. Richardson, 2015, Health technology assessment.

Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial

P. Roderick, M. Thursz, P. Richardson, 2013, Trials.

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.

M. Manns, F. Tacke, C. Trautwein, 2018, Journal of hepatology.

Nonsteroidal anti-inflammatory drug-induced hepatotoxicity.

G. Aithal, C. Day, 2007, Clinics in liver disease.

The natural history of histologically proved drug induced liver disease

C. Day, P. Aithal, P G Aithal, 1999, Gut.

The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2

Q. Anstee, C. Day, 2015, Seminars in Liver Disease.

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Enzo Bonora, E. Bonora, G. Targher, 2010, The New England journal of medicine.

EASL clinical practical guidelines: management of alcoholic liver disease.

T. Roskams, F. Nevens, S. Mueller, 2012, Journal of hepatology.

Steatohepatitis: a tale of two "hits"?

C. Day, O. James, 1998, Gastroenterology.

Pathogenesis of alcohol‐induced liver disease: Classical concepts and recent advances

A. Diehl, C. Day, W. Syn, 2011, Journal of gastroenterology and hepatology.

Clinical but not histological factors predict long‐term prognosis in patients with histologically advanced non‐decompensated alcoholic liver disease

A. Burt, C. Day, I. Emmerson, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

E. Bjornsson, J. George, E. Bugianesi, 2013, Gastroenterology.

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

T. Therneau, J. Kench, G. Marchesini, 2007, Hepatology.

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

I. Guha, G. Aithal, W. Rosenberg, 2007, Hepatology.

Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury

C. Day, A. Daly, 2013 .

Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score

L S Murray, L. Murray, P. Hayes, 2005, Gut.

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease

G. Alexander, J. Ramage, W. Rosenberg, 2010, Gut.

Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop

R. Fontana, J. Serrano, R. Andrade, 2010, Hepatology.

Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment

D. Gauguier, I. Gut, M. Lathrop, 2019, Scientific Reports.

Liver under Constant Attack — From Fat to Viruses

S. Thorgeirsson, A. Lohse, C. Day, 2009 .

Non-alcoholic steatohepatitis: from cell biology to clinical practice.

H. Cortez‐Pinto, C. Day, M. D. de Moura, 2006, Journal of hepatology.

Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury.

M. Pirmohamed, P. Donaldson, G. Aithal, 2010, Journal of hepatology.

Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance

M. Walker, J. Grove, C. Day, 1998, Diabetologia.

7 The inheritance of alcoholic liver disease

C. Day, M. Bassendine, 1998 .

Gut Microbiota and Lifestyle Interventions in NAFLD

M. Trenell, D. Houghton, C. Day, 2016, International journal of molecular sciences.

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease

Timothy Hardy, Q. Anstee, C. Day, 2016, Gut.

The role of phosphatidic acid in platelet‐derived growth factor–induced proliferation of rat hepatic stellate cells

H. Reeves, A. Burt, C. Day, 2000, Hepatology.

The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study

Giorgio Saracco, Neeraj Bhala, N. Bhala, 2011, Hepatology.

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

K. Clément, S. Cockell, H. Cordell, 2020, Science Translational Medicine.

Candidate gene case-control association studies: advantages and potential pitfalls.

C. Day, A. Daly, 2001, British journal of clinical pharmacology.

Nonalcoholic fatty liver disease

V. Wong, B. Neuschwander‐Tetri, C. Sirlin, 2015, Nature Reviews Disease Primers.

Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.

A. Gasbarrini, C. Day, L. Miele, 2013, Current pharmaceutical design.

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

M. Daly, D. Goldstein, M. Nelson, 2011, Gastroenterology.

Extrahepatic effects of alcohol: an overview

H. Reeves, C. Day, 2002 .

The effect of gastritis on human gastric alcohol dehydrogenase activity and ethanol metabolism

M. Rawlins, C. Day, P. J. Kelly, 1995, Alimentary pharmacology & therapeutics.

Adverse physical effects of alcohol misuse

C. Day, E. Gilvarry, S. Stewart, 2008 .

QT prolongation and sudden cardiac death in patients with alcoholic liver disease

T. Butler, C. Day, R. Campbell, 1993, The Lancet.

Polymorphisms in Immunoregulatory Genes

P. Donaldson, C. Day, A. Daly, 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group

M. Pirmohamed, G. Aithal, A. Hasnat, 2014, European Journal of Clinical Pharmacology.

The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease.

M. Allison, J. Dufour, F. Betsou, 2020, Contemporary clinical trials.

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD

H. Reeves, C. Day, Marco Y. W. Zaki, 2016, Digestive Diseases and Sciences.

POLG determines the risk of sodium valproate induced liver toxicity

R. Fontana, P. Chinnery, R. Horvath, 2013 .

Polymerase γ Gene POLG determines the risk of sodium valproate‐induced liver toxicity

R. Fontana, P. Watkins, P. Chinnery, 2010, Hepatology.

The genetics of NAFLD

Q. Anstee, C. Day, 2013, Nature Reviews Gastroenterology &Hepatology.

Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes

M. Trenell, D. Houghton, L. Errington, 2018, Diabetologia.

Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers.

J. Whitfield, M. Pirmohamed, H. Cordell, 2020, The American journal of gastroenterology.

Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors

J. Whitfield, M. Pirmohamed, H. Cordell, 2020, Hepatology.

Brief Report: Genetics of Alcoholic Cirrhosis—GenomALC Multinational Study

J. Whitfield, H. Cordell, T. Foroud, 2015, Alcoholism, clinical and experimental research.

Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.

G. Targher, L. Bertolini, C. Day, 2007, Journal of hepatology.

Genetic modifiers of non-alcoholic fatty liver disease progression.

Q. Anstee, C. Day, A. Daly, 2011, Biochimica et biophysica acta.

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

K. Clément, H. Cordell, M. Allison, 2020, bioRxiv.

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.

Q. Anstee, C. Day, F. Oakley, 2016, Annual review of pathology.

Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

G. Aithal, C. Day, J. Leathart, 2000, Pharmacogenetics.

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease.

A. Lonardo, L. Adinolfi, C. Day, 2004, Gastroenterology.

Genetic association studies in drug-induced liver injury

C. Day, A. Daly, 2012, Drug metabolism reviews.

Tumour necrosis factor-a promoter polymorphisms in primary biliary cirrhosis

J. Newton, David E. J. Jones, J. Grove, 1999 .

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

J. Dufour, H. Reeves, A. Burt, 2014, Journal of hepatology.

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Christian Thoma, M. Trenell, C. Day, 2012, Journal of hepatology.

12. ALCOHOLIC LIVER DISEASE

C. Day, S. Stewart, 2004 .

Hepatic steatosis: Innocent bystander or guilty party?

C. Day, O. James, 1998, Hepatology.

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

K. Clément, S. Cockell, H. Cordell, 2020, Journal of hepatology.

University of Dundee Association of Liver Injury From Specific Drugs , or Groups of Drugs , With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study

M. Daly, M. Nelson, Yufeng Shen, 2022 .

A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease.

K. Baur, B. Stieger, J. Schmitt, 2010, Clinical science.

Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans

E. Gamazon, H. Cordell, N. Chalasani, 2016, Aging.

From NAFLD in clinical practice to answers from guidelines.

Fabio Nascimbeni, A. Lonardo, S. Bellentani, 2013, Journal of hepatology.

White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers

M. Hudson, A. Burt, C. Day, 2013, BMC Gastroenterology.

Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD

A. Lonardo, C. Day, L. Losi, 2012, Liver international : official journal of the International Association for the Study of the Liver.

A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis

M. Hudson, D. Jones, C. Day, 2002 .

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C

J. Grove, A. Burt, C. Day, 1998, Hepatology.

A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.

J. Whitfield, M. Pirmohamed, A. McQuillin, 2021, Journal of hepatology.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

K. Clément, G. Alexander, M. Allison, 2014, Nature Communications.

Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.

Q. Anstee, C. Day, D. Seth, 2016, Gastroenterology.

Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis.

J. Newton, J. Grove, D. Jones, 1999, Journal of hepatology.

Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.

G. Marchesini, A. Lonardo, S. Bellentani, 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation

J. V. van Meurs, D. Adams, L. Moons, 2005, Gut.

Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis

J. Newton, David E. J. Jones, J. Grove, 1999 .

TM6SF2 rs58542926 influences hepatic fibrosis

K. Clément, G. Alexander, M. Allison, 2015 .

TM 6 SF 2 rs 58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease

K. Clément, G. Alexander, M. Allison, 2014 .

Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial.

M. Trenell, S. Cassidy, K. Hollingsworth, 2015, Clinical science.

Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease.

G. MacGowan, Roy Taylor, M. Trenell, 2012, Journal of hepatology.

The degree of hepatic steatosis associates with impaired cardiac and autonomic function.

Roy Taylor, M. Trenell, D. Houghton, 2019, Journal of hepatology.

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

A. Burt, Q. Anstee, C. Day, 2013, European journal of gastroenterology & hepatology.

British Association for the Study of the Liver

A. Perelson, C. Dejong, Y. Ma, 1991 .

Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis

M. Allison, G. Auzinger, J. Neuberger, 2012, Gut.

Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease.

M. Trenell, D. Jakovljevic, J. Newton, 2013, Clinical science.

Nonalcoholic Fatty Liver Disease

Q. Anstee, C. Day, 2015, Seminars in Liver Disease.

Glucokinase links Krüppel‐like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease

S. Friedman, L. Bechmann, H. Reeves, 2012, Hepatology.

Alcohol and the liver

C. Day, 2002 .

Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease

L. N. Valenti, G. Marchesini, M. Zappa, 2010, Gut.

Falls and Fall-Related Injury Are Common in Older People with Chronic Liver Disease

J. Newton, David E. J. Jones, C. Day, 2012, Digestive Diseases and Sciences.

Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease.

J. Newton, David E. J. Jones, C. Day, 2010, Journal of hepatology.

Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance

J. Newton, A. Burt, C. Day, 2008, Gut.

Pain as a complication of use of opiate antagonists for symptom control in cholestasis.

M. Hudson, C. Day, O. James, 2003, Gastroenterology.

Functional Impairment in Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease Is Significant and Persists over 3 Years of Follow-Up

J. Newton, David E. J. Jones, C. Day, 2013, Digestive Diseases and Sciences.

Genes or environment to determine alcoholic liver disease and non‐alcoholic fatty liver disease

C. Day, C P Day, 2006, Liver international : official journal of the International Association for the Study of the Liver.

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

L. N. Valenti, C. Trautwein, S. Cockell, 2021, JHEP reports : innovation in hepatology.

Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism.

P. Kelly, M. Bennett, C. Day, 1995, Gut.

The management of alcoholic liver disease.

C. Day, S. Stewart, 2003, Journal of hepatology.

Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease

C. Day, A. Daly, S. Ballestri, 2011, Expert review of gastroenterology & hepatology.

Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol.

Ivana V. Yang, I. Yang, C. Day, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Non-Alcoholic Fatty Liver Disease in Older People

J. Newton, A. Burt, C. Day, 2009, Gerontology.

Benefits of lifestyle modification in NAFLD

C. Day, S. Harrison, 2007, Gut.

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial

Roy Taylor, M. Trenell, D. Houghton, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

900 RECOMBINANT LYSOSOMAL ACID LIPASE NORMALIZES LIVER WEIGHT, TRANSAMINASES AND HISTOPATHOLOGICAL ABNORMALITIES IN AN MODEL OF CHOLESTERYL ESTER STORAGE DISEASE

A. Burt, C. Day, M. Leavitt, 2011 .

Recombinant lysosomal acid lipase normalizes liver weight, transaminases and histopathological abnormalities in an in vivo model of cholesteryl ester storage disease

A. Burt, C. Day, A. Quinn, 2011 .

liver disease clinical outcomes in patients with chronic Enhanced liver fibrosis test can predict and

G. Alexander, J. Ramage, W. Rosenberg, 2022 .

The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids

Y. Oo, J. O'grady, C. Day, 2007, Gut.

TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?

E. Speliotes, Bratati Kahali, Q. Anstee, 2015, Gastroenterology.

Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease

J. Grove, C. Day, A. Daly, 2000, Gut.

Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease.

P. Chinnery, G. Hudson, G. Aithal, 2011, Mitochondrion.

Warfarin dose requirement and CYP2C9 polymorphisms

G. Aithal, C. Day, P. Kesteven, 1999, The Lancet.

Pure alcoholic fatty liver and progression to cirrhosis or fibrosis

A. Ho, A. Burt, C. Day, 1995, The Lancet.

Is necroinflammation a prerequisite for fibrogenesis?

C. Day, 1996, Hepato-gastroenterology.

Genetic studies to identify hepatic fibrosis genes and SNPs in human populations.

C. Day, 2005, Methods in molecular medicine.

A role for the pregnane X receptor in flucloxacillin‐induced liver injury

M. Pirmohamed, G. Aithal, C. Day, 2010, Hepatology.

Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort"☆ (J Hepatol [2020] 505-515).

K. Clément, S. Cockell, H. Cordell, 2021, Journal of hepatology.

A randomised controlled trial of calcineurin inhibitor (CNI) replacement with mycophenolate mofetil and steroids in liver transplant patients with renal dysfunction

J. O'grady, C. Day, D. Patch, 2004 .

Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis.

M. Vidali, R. Rolla, D. Vay, 2002, Hepatology.

Valine‐alanine manganese superoxide dismutase polymorphism is not associated with alcohol‐induced oxidative stress or liver fibrosis

M. Vidali, R. Rolla, D. Vay, 2002 .

Physical evidence for the presence of two forms of phosphatidate phosphohydrolase in rat liver.

C. Day, S. Yeaman, 1992, Biochimica et biophysica acta.

Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

J. Whitfield, M. Pirmohamed, H. Cordell, 2018, Alcohol.

Cognitive impairment in non-cirrhotic chronic liver disease is unrelated to liver disease severity but associated with ineffective baroreflex function

J. Newton, David E. J. Jones, G. Fattakhova, 2011, Gut.

Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor

M. Pirmohamed, P. Donaldson, G. Aithal, 2008 .

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis

E. McColl, D. Stocken, N. Steen, 2017, PloS one.

The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver.

M. Zappa, S. Fargion, C. Day, 2011, Journal of hepatology.

Can genetic influence in non‐alcoholic fatty liver disease be ignored?

Q. Anstee, C. Day, Yang-Lin Liu, 2016 .

Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers

Roy Taylor, M. Trenell, D. Houghton, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

127 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

L. N. Valenti, E. Bugianesi, E. Vanni, 2010 .

Resistance exercise improves liver fat and glucose control in people with non-alcoholic fatty liver disease

Sarah A. Moore, Roy Taylor, M. Trenell, 2011 .

Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells: effects of platelet-derived growth factor and extracellular nucleotides.

A. Burt, C. Day, M. Lorite, 2006, American journal of physiology. Gastrointestinal and liver physiology.

The potential role of genes in nonalcoholic fatty liver disease.

C. Day, 2004, Clinics in liver disease.

Liver: Can pentoxifylline secure its place in liver therapeutics?

C. Day, Stuart Kendrick, 2010, Nature Reviews Gastroenterology &Hepatology.

Orthostatic intolerance is common in chronic disease--a clinical cohort study.

J. Newton, W. Ng, David E. J. Jones, 2014, International Journal of Cardiology.